den Boer J A, Ravelli D P, Huisman J, Ohrvik J, Verhoeven W M, Westenberg H G
University Hospital, Department of Biological Psychiatry, Utrecht, The Netherlands.
Acta Psychiatr Scand Suppl. 1990;358:108-10. doi: 10.1111/j.1600-0447.1990.tb05300.x.
Seventy-one patients were entered into a multicentre, double-blind randomized study to compare the efficacy and safety of remoxipride with those of haloperidol in the acute treatment of schizophrenia or schizophreniform disorder. The patients, who were well-matched regarding demographic characteristics, were aged 18-64 years. Four patients in the remoxipride group and 6 in the haloperidol group discontinued treatment prematurely. The mean daily doses during the last week of treatment were 363 mg remoxipride and 9 mg haloperidol. At this time 22% of patients on remoxipride and 66% of those on haloperidol were taking anticholinergics (p less than 0.001). The clinical efficacy was similar in both groups as judged by Present State Examination (PSE) profile and Brief Psychiatric Rating Scale (BPRS) ratings. Several adverse symptoms occurred significantly more frequently during treatment with haloperidol than with remoxipride, particularly where extrapyramidal symptoms were concerned. No clinically relevant changes occurred in the laboratory tests in either group.
71名患者进入一项多中心、双盲随机研究，以比较瑞莫必利与氟哌啶醇在急性治疗精神分裂症或精神分裂症样障碍中的疗效和安全性。这些患者在人口统计学特征方面匹配良好，年龄在18至64岁之间。瑞莫必利组有4名患者和氟哌啶醇组有6名患者提前终止治疗。治疗最后一周的平均日剂量分别为瑞莫必利363毫克和氟哌啶醇9毫克。此时，服用瑞莫必利的患者中有22%、服用氟哌啶醇的患者中有66%正在服用抗胆碱能药物（p<0.001）。根据现况检查（PSE）概况和简明精神病评定量表（BPRS）评分判断，两组的临床疗效相似。与瑞莫必利相比，氟哌啶醇治疗期间出现的几种不良症状明显更频繁，尤其是锥体外系症状。两组的实验室检查均未出现临床相关变化。
